SG11201908796XA - Improved antigen binding receptors - Google Patents

Abstract

ATMCD TM CSD CD28 VH CH VL CL linker (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 04 October 2018 (04.10.2018) WIPO I PCT omit Ill °nolo ow (10) International Publication Number WO 2018/177966 Al (51) International Patent Classification: A61K 39/395 (2006.01) C07K 14/735 (2006.01) A61K 35/17 (2015.01) C07K 16/28 (2006.01) C07K 14/725 (2006.01) C07K 16/30 (2006.01) C07K 14/705 (2006.01) A61K 39/00 (2006.01) (21) International Application Number: PCT/EP2018/057566 (22) International Filing Date: 26 March 2018 (26.03.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 17163090.8 27 March 2017 (27.03.2017) EP (71) Applicant (for all designated States except US): F. HOFF- MANN-LA ROCHE AG [CH/CH]; Grenzacherstrasse 124, 4070 Basel (CH). (71) Applicant (for US only): HOFFMANN-LA ROCHE INC. [US/US]; Overlook at Great Notch, 150 Clove Road, 8th Floor, Suite 8 - Legal Department, Little Falls, New Jer- sey 07424 (US). (72) Inventors: STUBENRAUCH, Kay-Gunnar; c/o Roche Diagnostics GmbH, Nonnenwald 2, 82377 Penzberg (DE). MOESSNER, Ekkehard; c/o Roche Glycart AG, Wagis- trasse 18, 8952 Schlieren (CH). KLEIN, Christian; c/o Roche Glycart AG, Wagistrasse 18, 8952 Schlieren (CH). DAROWSKI, Diana; c/o Roche Glycart AG, Wagistrasse 18, 8952 Schlieren (CH). (74) Agent: BRODBECK, Michel; Grenzacherstrasse 124, 4070 Basel (CH). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (54) Title: IMPROVED ANTIGEN BINDING RECEPTORS Figure 1A Figure 1B anti P329G linker VL linker ATM CD28 TM CSD CD28 SSD CD3z anti P329G ATM = anchoring transmembrane domain CSD = co-stimulatory signaling domain SSD CD3z SSD = stimulatory signaling domain scFv Format Fab Format N N (57) : The present disclosure generally relates to antigen binding receptors capable of specific binding to mutated Fc domains 1-1 with reduced Fc receptor binding and T cells expressing these antigen binding receptors. More precisely the application deals with an c)1: 1-1 engineered Fc receptor consisting of a CD3 intracellular domain coupled to CD28 internal and transmembrane domains. The extracel- lular part preferably consists of an anti Pro329Gly antibody variable domain. Uses in cancer therapy and diagnosis C [Continued on next page] WO 2018/177966 Al IMEDIMOMMIONE1013010BEHOIMOVOIMIE SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to the identity of the inventor (Rule 4.17(0) of inventorship (Rule 4.17(iv)) Published: — with international search report (Art. 21(3)) — with sequence listing part of description (Rule 5.2(a))